MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
10 September 2021 - 12:15AM
Business Wire
MyMD to highlight its development pipeline for
MYMD-1, an immunometabolic regulator, and Supera-CBD, a synthetic
cannabidiol derivative
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the
Company”), a clinical stage pharmaceutical company committed to
extending healthy lifespan, will present at the H.C. Wainwright
23rd Annual Global Investment Conference being held virtually
September 13-15, 2021.
MyMD’s presentation video will be available for viewing on
demand starting at 7:00 am ET on Monday, September 13th, and
management will be available for one-on-one meetings with investors
upon request. Investors may register for the conference at the
event website. The live and archived webcast will be available for
90 days after the event.
During this presentation, Chris Chapman, M.D., President,
Director and Chief Medical Officer, and Adam Kaplin, M.D., PhD,
Chief Scientific Officer will discuss the multiple indications for
each of MyMD’s novel drug candidates. The MYMD-1 drug platform is
being developed to target aging (sarcopenia), autoimmune diseases
and immune-mediated depression, and shows potential as an
anti-fibrotic and anti-neoplastic therapeutic. MYMD-1 is also being
developed as a potential therapy for COVID-19-related conditions
such as post-COVID-19 syndromes. Supera-CBD is being developed to
address anxiety, chronic pain, addiction, and seizures, and is on a
path toward human clinical trials as a therapy for epilepsy,
followed by chronic pain. It also has the potential to address the
significant unmet need for medications to treat stimulant
addictions – specifically cocaine, methamphetamine – as well as
opioid use disorders.
About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals,
Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company
committed to extending healthy lifespan, is focused on developing
two novel therapeutic platforms that treat the causes of disease
and decline rather than only addressing the symptoms. MYMD-1 is a
drug platform based on a clinical stage small molecule that
regulates the immunometabolic system to control TNF-α, a driver of
chronic inflammation, and other pro-inflammatory cell signaling
cytokines. MYMD-1 is being developed to treat aging and longevity,
autoimmune diseases, and COVID-19- associated depression and
cytokine elevation. The Company’s second drug platform, Supera-CBD,
is being developed to treat chronic pain, addiction and epilepsy.
Based on a novel synthetic derivative of cannabidiol (CBD),
Supera-CBD is being developed to address the rapidly growing CBD
market, which includes both FDA approved drugs and CBD products not
currently regulated as drugs. For more information, visit
www.mymd.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates; the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates; the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the Quarterly Report on Form 10-Q for the
quarterly period ended June 30, 2021, filed by MyMD on August 16,
2021. Forward-looking statements speak only as of the date they are
made and MyMD disclaims any intention or obligation to revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210909005072/en/
Investor: Robert Schatz (646) 421-9523 rschatz@mymd.com
www.mymd.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Apr 2024 to May 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From May 2023 to May 2024